Live Terminal | Security Analysis of 2256.HK
TERMINAL beta
Version: 0.1
Timestamp: 1708840843.708097
Options
100220.KS
52.83%
1809.TW
51.88%
006220.KS
49.51%
0756.HK
49.35%
B7J.DE
48.43%
0T8B.F
-39.43%
009310.KS
-40.63%
SZGPF
-42.69%
GOLL4.SA
-52.40%
HGEN.L
-53.60%
AAPL $182.88 -0.81%
AMD $176.41 -3.00%
AMZN $174.58 0.00%
BRK-B $417.87 0.65%
GOOG $145.44 0.08%
IBM $185.76 0.84%
INTC $43.28 0.71%
JNJ $161.87 0.89%
JPM $184.12 0.57%
META $488.06 0.40%
MSFT $410.31 -0.33%
O $53.27 0.85%
TSLA $195.04 -1.20%
WMT $176.24 0.47%
QQQ $436.78 -0.2945%
TLT $93.87 1.3387%
VUSA.DE $89.31 0.4025%
VUAA.DE $88.65 0.3918%
FJPR.L $5.64 1.5565%
VWRP.L $97.83 0.1638%
VWRL.L $98.54 0.1626%
EMGU.L $3.60 -0.1111%
RDVY $52.42 0.3446%
FLOT $50.98 0.0000%
SCHZ $45.74 0.4171%
IBB $138.19 0.7436%
C020.DE $21.34 0.0000%
DFAX $24.72 0.0810%
LYP6.DE $226.20 0.4440%
MEUD.PA $226.19 0.4173%
IDWR.L $71.10 0.4521%
IQQW.DE $65.72 0.3972%
EXS1.DE $145.70 0.2477%
XESC.L $6865.00 0.1240%
DFAU $35.25 0.0852%
ACWV $104.02 0.2602%
VHYD.L $63.92 0.2746%
VGWD.DE $59.24 0.5602%
FXKZ.ME $303.00 0.0000%

Latest articles

No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.

Sentiment statistics ?
2256.HK
μ null
null
null

Financial Histories

Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.

Overview
2256.HK
Latest Performance
2256.HK$2.54
$0.14 • 5.83%
2256.HK
Price 2.54
Change Pct 5.83
Change Abs 0.14
Market Cap 1.8 billion
Eps -0.88
Pe Ratio -2.89
Outstanding Shares 695.1 million
Volume 737000
Avg Volume 2.4 million
Industry Biotechnology
Sector Name Health Care
Country Short Name CN
Announcement Earnings 2024-03-11 03:00:59+00:00
All metrics in USD or %.
Dividends

There is no dividend data to display. Refer our Dividend calendar for other accurate data.

Risk Profiles

Please sign up and become a member to view all risk profiles.

Competitors/Peer Groups
2256.HK
Focus

The 'Focus' Area is meant to be an One-Pager about all Important Insights, Risks and Opportunities to solely analyze a single corporate.

Company descriptions
2256.HK

Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, discovers and develops small molecule oncology therapies in the People's Republic of China. Its product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. The company's primary product candidates are ABSK011, a small molecule inhibitor of fibroblast growth factor receptor 4 for the treatment of advanced hepatocellular carcinoma with hyper-activation of FGF19/FGFR4 signaling; and ABSK091, a molecularly targeted product candidate for the treatment of multiple solid tumors, including urothelial cancer, gastric cancer, cholangiocarcinoma, and lung cancer.